Tait D. Shanafelt, MD; John C. Byrd, MD; Timothy G. Call, MD; Clive S. Zent, MD; Neil E. Kay, MD
Grant Support: Salary support from National Cancer Institute (K12 CA90628) (Dr. Shanafelt) and partial salary support from the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274) (Drs. Shanafelt and Zent). Dr. Byrd is a clinical scholar of the Leukemia and Lymphoma Society. The authors thank Mr. Edson Spencer and Mr. Robert Donner for continued philanthropic support.
Potential Financial Conflicts of Interest: Grants received: C.S. Zent (Berlex, Genentech); Grants pending: T. Shanafelt (Berlex Corp.).
Requests for Single Reprints: Tait D. Shanafelt, MD, Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street, Rochester, MN 55902.
Current Author Addresses: Drs. Shanafelt, Call, Zent, and Kay: Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street, Rochester, MN 55902.
Dr. Byrd: Ohio State University, B302 Starling-Loving Hall, 320 West 10th Avenue, Columbus, OH 43210.
Chronic lymphocytic leukemia is one of the most common malignant lymphoid diseases in the western world and is frequently diagnosed by internists. There have been clinically significant changes in method of diagnosis, prognostic tools, supportive care, and treatment over the past 2 decades. Most patients with chronic lymphocytic leukemia now have Rai stage 0 or I disease at diagnosis. Patients with early-stage disease are a heterogeneous group: Approximately 30% to 50% will have accelerated disease progression, and the remainder may live for decades and possibly never require therapy. Recent insights into the biological characteristics of leukemic B cells have led to the discovery of new prognostic tools (immunoglobulin variable-region heavy chain gene mutation status, cytogenetic abnormalities assessed by fluorescent in situ hybridization, and Z-chain–associated protein kinase-70 protein expression) that can identify patients with early-stage disease who are at high risk for early disease progression. These tools allow physicians to individualize counseling, follow-up, and management on the basis of disease risk. In addition, new treatments developed over the past 2 decades (purine nucleoside analogues, monoclonal antibodies, and combination chemoimmunotherapy regimens) have dramatically improved response rates and appear to prolong survival. In this review, the authors discuss the current work-up of lymphocytosis and highlight how to use recently identified prognostic tools to stratify risk in patients with newly diagnosed, early-stage chronic lymphocytic leukemia. Recommendations for patient counseling, follow-up, supportive care, and initial treatment are presented for each risk category.
Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE. Narrative Review: Initial Management of Newly Diagnosed, Early-Stage Chronic Lymphocytic Leukemia. Ann Intern Med. 2006;145:435–447. doi: 10.7326/0003-4819-145-6-200609190-00007
Download citation file:
Published: Ann Intern Med. 2006;145(6):435-447.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use